Boothbay Fund Management’s Akero Therapeutics AKRO Stock Holding History

Boothbay Fund Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,100	Closed	-$717K	–	1930
2025 Q3	$717K	Sell	15,100 -1,100	-7%	-$53.3K	0.01%	986
2025 Q2	$864K	Buy	+16,200	New	+$736K	0.02%	737
2023 Q4	–	Sell	-40,000	Closed	-$2.02M	–	1624
2023 Q3	$2.02M	Buy	+40,000	New	+$1.86M	0.05%	491
2022 Q4	–	Sell	-7,000	Closed	-$238K	–	1971
2022 Q3	$238K	Buy	+7,000	New	+$107K	0.01%	1686

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Boothbay Fund Management's AKRO Position: Q4 2025 in Review

Boothbay Fund Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 64,258 shares — an estimated $3.05M sold.

Boothbay Fund Management first reported a position in AKRO in Q4 2019 and held it in 6 quarters. The position peaked at $3.39M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Boothbay Fund Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Boothbay Fund Management sold 64,258 Akero Therapeutics shares in Q4 2025, an estimated $3.05M.
Boothbay Fund Management first reported a position in Akero Therapeutics in Q4 2019 and held it in 6 quarters.
Boothbay Fund Management's Akero Therapeutics position peaked at $3.39M in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.